肾上腺皮质功能不全合并COVID-19患者的临床转归及影响因素

doi:10.16352/j.issn.1001-6325.2024.09.1290

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (9): 1290-1297.doi: 10.16352/j.issn.1001-6325.2024.09.1290

肾上腺皮质功能不全合并COVID-19患者的临床转归及影响因素

周翔^1#, 许轶婧^2#, 刘艺文¹, 朱惠娟¹, 卢琳^1*

1.中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室疑难重症及罕见病国家重点实验室,北京 100730;
2.中国医学科学院北京协和医学院临床医学专业(八年制),北京 100730

收稿日期:2024-01-02 修回日期:2024-04-01 出版日期:2024-09-05 发布日期:2024-08-30
通讯作者: ^*lulin88@sina.com
作者简介:^#对本文有相同贡献
基金资助:
中央高水平医院临床科研业务费资助(2022-PUMCH-A-156);国家重点研发计划常见多发病防治研究专项(2022YFC2505300,子课题:2022YFC2505304)

Clinical outcomes and risk factors of COVID-19 patients with adrenal insufficiency

ZHOU Xiang^1#, XU Yijing^2#, LIU Yiwen¹, ZHU Huijuan¹, LU Lin^1*

1. Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
2. Eight-year Medical Doctor Program, CAMS & PUMC, Beijing 100730, China

Received:2024-01-02 Revised:2024-04-01 Online:2024-09-05 Published:2024-08-30
Contact: ^*lulin88@sina.com

摘要/Abstract

摘要： 目的总结肾上腺皮质功能不全(AI)合并新型冠状病毒感染(COVID-19)患者的临床特征及转归情况,分析影响转归的危险因素。方法回顾性分析2022年12月北京协和医院收治的发生COVID-19的AI患者的临床特征,并对其进行随访以收集其疾病转归情况。结果共纳入28例AI合并COVID-19患者,20例(71.4%)接受糖皮质激素基础替代。18例院外发生COVID-19患者中,11例(61.1%)居家主动加量糖皮质激素。感染后最常见症状为发热(96.4%)、消化道症状(82.1%)、意识障碍(78.6%)。出现重度意识障碍与年龄大、糖皮质激素基础替代剂量低相关(P＜0.05)。20例(71.4%)患者发生肾上腺危象(AC),与糖皮质激素基础替代剂量低、低氯血症、嗜酸性粒细胞低、血小板低、活化部分凝血活酶时间(APTT)长相关(P＜0.05)。2例患者死亡。26例存活患者中,意识恢复时间大于48小时者占26.3%(5/19),意识延迟恢复与入院收缩压低、血肌酐高、纤维蛋白原高相关(P＜0.05)。48.0%(12/25)患者出现疲乏、纳差等长新冠症状。糖皮质激素加量的患者中,50.0%(12/24)于3周内恢复至基线激素剂量。结论 AI合并COVID-19患者出现意识障碍及AC的风险较高。AI患者在感染应激期间主动加量糖皮质激素的意识不足,临床应加强对AI患者的“病期规则”教育。

关键词: 肾上腺皮质功能不全, 新型冠状病毒感染, 意识障碍, 肾上腺危象

Abstract: Objective To summarize the clinical characteristics and outcomes of corona virus disease 2019(COVID-19) in patients with adrenal insufficiency (AI), and analyze the risk factors of outcomes. Methods The clinical data of COVID-19 patients with AI in Peking Union Medical College Hospital in December 2022 were analyzed retrospectively and the patients were followed up to collect outcomes of their diseases. Results Among 28 COVID-19 patients with AI, 20 cases (71.4%) received basal corticosteroid replacement. Among the 18 patients with community-acquired COVID-19, 11 cases (61.1%) increased the corticosteroid dosage proactively at home. The most common symptoms of COVID-19 were fever (96.4%), gastrointestinal symptoms (82.1%) and consciousness disturbance (78.6%). Occurrence of severe consciousness disturbance was associated with older age and lower basal corticosteroid replacement dose(P＜0.05). Adrenal crisis(AC) occurred in 20 patients(71.4%), which was associated with lower basal corticosteroid replacement dose, hypochloremia, lower eosinophil, lower platelet, and longer activated partial thromboplastin time(APTT)(P＜0.05). 2 patients died during hospitalization.26.3 % (5/19) of surviving patient′s recovered consciousness longer than 48 hours. Delayed recovery of consciousness was associated with lower systolic pressure, higher blood creatinine, and higher fibrinogen(P＜0.05). Long COVID-19 symptoms such as fatigue and poor appetite occurred in 48.0 % (12/25) of patients. Among patients with increased corticosteroid dosage, 50.0 % (12/24) had their dose reduced to baseline within 3 weeks. Conclusions COVID-19 patients with AI have a high frequency of consciousness disturbance and AC. AI patients are lack of awareness of adjusting corticosteroid dosage proactively in case of infection stress, thus education of “sick day rules” for AI patients should be strengthened in clinical practice.

Key words: adrenal insufficiency, corona virus disease 2019, consciousness disturbance, adrenal crisis

中图分类号:

R586.1

周翔, 许轶婧, 刘艺文, 朱惠娟, 卢琳. 肾上腺皮质功能不全合并COVID-19患者的临床转归及影响因素[J]. 基础医学与临床, 2024, 44(9): 1290-1297.

ZHOU Xiang, XU Yijing, LIU Yiwen, ZHU Huijuan, LU Lin. Clinical outcomes and risk factors of COVID-19 patients with adrenal insufficiency[J]. Basic & Clinical Medicine, 2024, 44(9): 1290-1297.

参考文献 15

[1]	Alzahrani AS,Mukhtar N,Aljomaiah A,et al. The impact of COVID-19 viral infection on the hypothalamic-pituitary-adrenal axis[J]. Endocr Pract,2021,27: 83-89.
[2]	Allolio B. Extensive expertise in endocrinology: adrenal crisis[J]. Eur J Endocrinol,2015,172: R115-R124.
[3]	Yedinak C,Ross IL. Significant risk of COVID-19 and related-hospitalization among patients with adrenal insufficiency: a large multinational survey[J]. Front Endocrinol(Lausanne),2022,13: 1042119. doi:10.3389/fendo.2022.1042119.
[4]	Jensterle M,Herman R,Janež A, et al. The relationship between COVID-19 and hypothalamic-pituitary-adrenal axis: a large spectrum from glucocorticoid insufficiency to excess-the CAPISCO international expert panel[J]. Int J Mol Sci, 2022, 23: 7326. doi:7310.3390/ijms23137326.
[5]	Grinspoon SK, Biller BM. Clinical review 62: laboratory assessment of adrenal insufficiency[J]. J Clin Endocrinol Metab, 1994, 79: 923-931.
[6]	新型冠状病毒感染诊疗方案(试行第十版)[J]. 中国医药, 2023, 18: 161-166.
[7]	新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中国医药, 2022, 17: 481-487.
[8]	Teasdale G, Maas A, Lecky F, et al. The Glasgow Coma Scale at 40 years: standing the test of time[J]. Lancet Neurol, 2014, 13: 844-854.
[9]	Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults[J]. JAMA Netw Open, 2022, 5:e2238804. doi:10.1001/jamanetworkopen.2022.38804.
[10]	Ono Y, Ono S, Yasunaga H, et al. Clinical features and practice patterns of treatment for adrenal crisis: a nationwide cross-sectional study in Japan[J]. Eur J Endocrinol, 2017, 176: 329-337.
[11]	Beghi E, Giussani G, Westenberg E, et al. Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions[J]. J Neurol, 2022, 269: 2265-2274.
[12]	Castinetti F, Amodru V, Brue T. Adrenal crisis may occur even in patients with asymptomatic COVID-19[J]. Endocr Pract, 2020, 26: 929-930.
[13]	Suryadevara V, Merugu C, Perumal NL, et al. Adrenal crisis in a patient with APS2 due to COVID-19: a case report[J]. J Family Med Prim Care, 2022, 11: 2228-2230.
[14]	Tan T, Khoo B, Mills EG, et al. Association between high serum total cortisol concentrations and mortality from COVID-19[J]. Lancet Diabetes Endocrinol, 2020, 8: 659-660.
[15]	Arlt W, Baldeweg SE, Pearce SHS, et al. Endocrinology in the time of COVID-19: management of adrenal insufficiency[J]. Eur J Endocrinol, 2020, 183: G25-G32.

肾上腺皮质功能不全合并COVID-19患者的临床转归及影响因素

Clinical outcomes and risk factors of COVID-19 patients with adrenal insufficiency

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 15

相关文章 2

编辑推荐

Metrics

本文评价

[1]	张毅, 申乐. 新型冠状病毒感染患者术后并发症及相关危险因素[J]. 基础医学与临床, 2024, 44(3): 408-411.
[2]	戴靖榕, 肖宝, 李霖, 胡江英, 刘斌. 影响老年新型冠状病毒感染患者院内死亡的因素及风险预测模型的构建[J]. 基础医学与临床, 2024, 44(1): 92-97.